Even after sharp sales drop, Pfizer sees bright side with priority review voucher from Paxlovid approval
In a change of pace from the recent COVID-related business struggles for Pfizer, the drugmaker has picked up a valuable reward from the FDA in the form of a priority review voucher (PRV). The agency doled out the PRV after determining that Pfizer's …